Navigation Links
Genzyme Announces Data from First Phase 3 Study of Tolevamer in,Patients with C. difficile Associated Diarrhea

CAMBRIDGE, Mass., July 06, 2007 /PRNewswire-FirstCall/ -- Genzyme Corp. announced top-line data today from the first of two Phase 3 clinical studies to assess the safety and efficacy of tolevamer liquid, an investigational, non-antibiotic, polymer therapy for patients with Clostridium difficile associated diarrhea (CDAD). The second Phase 3 study of tolevamer liquid is fully enrolled and results are expected later this year.

In this first Phase 3 study known as the Polymer Alternative for CDAD Treatment (PACT) study, tolevamer liquid did not meet its primary endpoint of non-inferiority to the standard prescribed oral dose of the antibiotic vancomycin, as measured by the percent of patients with resolution of CDAD. This result contrasts with the findings from Genzyme's earlier Phase 2 study of a solid oral dosage formulation of tolevamer that met its primary endpoint of non-inferiority compared to vancomycin.

Consistent with recent published studies, high rates of CDAD recurrences were observed in patients treated with either vancomycin or metronidazole. High CDAD recurrence rates were not observed in patients treated with tolevamer liquid. Tolevamer liquid was generally well tolerated with no unanticipated safety concerns. Data from this first Phase 3 study is expected to be presented at a future medical conference.

"These are disappointing results that alter our expectations about the potential for commercializing tolevamer in the near future," stated Henri A. Termeer, chairman and chief executive officer of Genzyme Corp. "The results of our second Phase 3 study will be available later this year and will help us determine what contribution tolevamer might be able to make in addressing this serious unmet medical need."

C. difficile has become one of the most significant infection control concerns in healthcare today. Physicians worldwide are confronting a worsening epidemic, with an
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Genzyme Announces Results of Clinical Trial of Hylastan
2. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
5. Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:5/23/2013)... May 23, 2013 SynCardia Systems, Inc. ( ... FDA, Health Canada and CE ( Europe ... Glasgow Science Centre in Scotland , ... the SynCardia temporary Total Artificial Heart powered ... $3 million Bodyworks Exhibition, one of the most advanced ...
(Date:5/23/2013)... May 23, 2013 InspireMD, ... the leader in embolic protection stents, today announced ... Acute ST Elevation Reperfusion) trial demonstrating that the ... and drug eluting stents in all-cause mortality in ... from the trial were presented at the InspireMD ...
(Date:5/23/2013)... 2013  PAREXEL International Corporation (NASDAQ: PRXL ... the Jefferies Healthcare Conference in New York.  ... Financial Officer, will be making a presentation on PAREXEL ... June 3, 2013. A live webcast of ... of PAREXEL,s website at www.PAREXEL.com in the ...
Breaking Medicine Technology:Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 2Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 3InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 2InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 3InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 4InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 5PAREXEL International To Present At Jefferies Healthcare Conference 2
... , , , , ... a Bay(R) Pharmaceuticals , Inc. (NYSE-Amex: NBY ... treatment or prevention of a wide range of bacterial, viral, and ... Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, ...
... , , , ... (Nasdaq: WHRT ) - World Heart Corporation (WorldHeart) announced today ... of the Levacor Ventricular Assist Device (VAD) at ten US centers. ... information to the FDA within 45 days, but the study is permitted to ...
Cached Medicine Technology:NovaBay Pharmaceuticals to Present New Data on Lead Anti-Infective Compound at the 2009 ICAAC Annual Meeting 2NovaBay Pharmaceuticals to Present New Data on Lead Anti-Infective Compound at the 2009 ICAAC Annual Meeting 3WorldHeart Receives US Clinical Study Approval for the Levacor(TM) VAD 2WorldHeart Receives US Clinical Study Approval for the Levacor(TM) VAD 3
(Date:5/23/2013)... a year ago, the leading journal Science ... drug. A significant breakthrough and an important starting point ... De Strooper Alzheimer,s researcher at VIB and KU ... D,Hooge KU Leuven and scientists at Janssen ... Alzheimer,s animal test models. Their results were different, as ...
(Date:5/23/2013)... May 23, 2013 Live ... contemporary services, provides the best business lead solution ... Its Call center Management solution features Free Web ... Call Limitation, Do-Not-Call Maintenance and "Automatic Transfer Retry". ... comprehensive campaign delivery and management system. , Its ...
(Date:5/23/2013)... ROCHESTER, Minn. -- Mayo Clinic researchers have used next ... more aggressive prostate cancer tumors have similar genetic origins, ... appear online today in the journal Cancer Research ... DNA alterations using next generation sequencing in adjacent Gleason ... genomics with changes in pathology," says ,John Cheville, M.D., ...
(Date:5/23/2013)... New York, New York (PRWEB) May 23, 2013 ... products manufactured by C.R. Bard, Inc., continue to move ... District Court, Southern District of West Virginia, Bernstein Liebhard ... 17th, the Court denied a request by C.R. Bard ... claimed would reveal trade secrets and other confidential, proprietary ...
(Date:5/23/2013)... The vast majority of Americans believe it’s ... their level of physical activity, the healthfulness of their ... taking that control. Those are among the findings ... Food & Health Survey. , According to the Survey, ... “a great deal of control” or “complete control” over ...
Breaking Medicine News(10 mins):Health News:New insights contradict promising Alzheimer's research 2Health News:Live Lead Pros Announces The Benefits of Comprehensive Campaign Delivery and Management System 2Health News:Mayo Clinic genomic analysis lends insight to prostate cancer 2Health News:Transvaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Order in Federal C.R. Bard Mesh Implant Lawsuits 2Health News:Transvaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Order in Federal C.R. Bard Mesh Implant Lawsuits 3Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 2Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 3Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 4
... already collaborating on several projects, including the mapping of ... bacteria, compiled from 577 billion base pairs of sequence ... this work as one of the scientific breakthroughs of ... in life sciences, healthcare and agricultural research. Henry ...
... In their search for new, better ways to diagnose ... discovered that measurement of C-reactive protein in the synovial ... white blood cell count (WBC) and the percentage of ... minimal role in the determination of PJI. , The ...
... HealthDay Reporter , MONDAY, Feb. 6 (HealthDay News) -- ... diabetes, the first line of defense is lifestyle changes such ... those lifestyle changes don,t get blood sugar levels under control, ... as the first oral treatment that should be given. ...
... have, for the first time, described the genetic basis of ... by chronic pelvic pain and infertility. The researchers, discovery of ... Published in the Feb. 3 early online issue of ... mutation located in part of the KRAS gene, which leads ...
... HealthDay Reporter , MONDAY, Feb. 6 (HealthDay News) -- ... in cars, more than 20 percent of nonsmoking teens still ... particularly intense in a closed space, such as inside a ... "There have been marked decreases in exposure to smoking ...
... , MONDAY, Feb. 6 (HealthDay News) -- ... processing information in men, but not in women, new research ... more reason to quit the habit. "This study underscores ... smoking is a modifiable risk factor with an effect size ...
Cached Medicine News:Health News:VIB and BGI organize joint genomics meeting, Feb. 15, 2012, Belgium 2Health News:VIB and BGI organize joint genomics meeting, Feb. 15, 2012, Belgium 3Health News:Metformin Preferred Drug for Type 2 Diabetes, Experts Say 2Health News:Metformin Preferred Drug for Type 2 Diabetes, Experts Say 3Health News:Gene mutation discovery sparks hope for effective endometriosis screening 2Health News:Fewer Teens Exposed to Tobacco Smoke in Cars: Report 2Health News:Fewer Teens Exposed to Tobacco Smoke in Cars: Report 3Health News:Smoking May Be Especially Tough on Men's Brains 2
... When Welch Allyn designed the ... in 1915, they began a tradition ... eye care professionals worldwide. In keeping ... introduces the prestigious 3.5v Coaxial-plus Ophthalmoscope. ...
Welch Allyn quality in a convenient pocket size. The PocketScope fits into your pocket! Easy to use, lightweight, and perfect for general and specialist use. Take your PocketScope with you everywhere...
... ALE-3600 and ALE-3600PC Patternless ... fit lenses to frames, ... the convenience of complete ... edgers are particularly suited ...
... the features of the FR-20 Frame Reader with ... no longer need to connect the frame reader ... capable of receiving data via a cable from ... to streamline your edging operations. It stores the ...
Medicine Products: